Background
Broadly neutralizing antibody (bNAb) 1-18, targeted against the CD4-binding site (CD4bs) on the HIV-1 envelope protein, is a potentially promising tool for shaping future therapeutic and cure-focused clinical strategies against HIV-1. To enhance 1-18’s clinical potential, we introduced half-life-extending LS mutations and evaluated the resulting bNAb, BNT351.
Methods
Affinity for neonatal Fc receptor (FcRn) was measured via surface plasmon resonance. Pharmacokinetic studies were performed in Tg32 mice expressing human FcRn, and non-human primates (NHPs). Human half-life was predicted by allometric scaling of animal data. A pseudovirus neutralization test (pVNT) was used to evaluate neutralization potency and breadth. To evaluate in vivo antiviral activity, HIV-1YU2-infected humanized CD34+ NSG mice were injected with BNT351 or saline for 8 weeks (subcutaneous, twice/week) and plasma viremia was monitored for 17 weeks via RT-qPCR. Rebound viruses were sequenced and tested for BNT351 susceptibility via pVNT. Off-target profiling was performed using the Retrogenix® cell microarray with ~6,500 human proteins. As part of developability testing, stability under stress conditions was evaluated by LC-MS/MS.
Results
LS mutations increased the affinity of BNT351 to human FcRn 20-fold, resulting in an extended half-life of 10–14 days in Tg32 mice and 18 days in NHPs, with a predicted human half-life of ~50 days. BNT351 retained 1-18’s exceptional neutralization potency and breadth of 97% at a geometric mean of IC50 < 1 µg/mL against a 119-strain HIV-1 multiclade panel. Moreover, BNT351 neutralized clade C strains (n=106) from the Antibody Mediated Prevention panel, representative of circulating HIV-1 strains, with high potency (geometric mean of IC50=0.13 µg/mL) and breadth (77%), outperforming clinically tested CD4bs-targeting bNAbs VRC01 and 3BNC117. BNT351 fully suppressed viremia in HIV-1-infected humanized CD34+ NSG mice without selecting for viral resistance. Additionally, BNT351 showed no off-target binding, and only low degradation levels under stress conditions.
Conclusions
BNT351, featuring LS mutations, showed extended half-life in animal models, while maintaining the exceptional antiviral in vitro and in vivo activity of its parental bNAb 1-18. When considered alongside the favorable developability assessment, no off-target binding, and low viral escape risk, we have selected BNT351 for clinical development, which is expected to begin in 2026.